AIM: To assess red blood cell (RBC) transfusion effects on acute kidney injury (AKI) after transcatheter aortic valve replacement (TAVR). METHODS: A literature search was performed using MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and clinicaltrials.gov from the inception of the databases through December 2015. Studies that reported relative risk, odds ratio or hazard ratio comparing the risks of AKI following TAVR in patients who received periprocedural RBC transfusion were included. Pooled risk ratio (RR) and 95%CI were calculated using a random-effect, generic inverse variance method. RESULTS: Sixteen cohort studies with 4690 patients were included in the analyses to assess the risk of AKI after TAVR in patients who received a periprocedural RBC transfusion. The pooled RR of AKI after TAVR in patients who received a periprocedural RBC transfusion was 1.95 (95%CI: 1.56-2.43) when compared with the patients who did not receive a RBC transfusion. The meta-analysis was then limited to only studies with adjusted analysis for confounders assessing the risk of AKI after TAVR; the pooled RR of AKI in patients who received periprocedural RBC transfusion was 1.85 (95%CI: 1.29-2.67). CONCLUSION: Our meta-analysis demonstrates an association between periprocedural RBC transfusion and a higher risk of AKI after TAVR. Future studies are required to assess the risks of severe AKI after TAVR requiring renal replacement therapy and mortality in the patients who received periprocedural RBC transfusion.
AIM: To assess red blood cell (RBC) transfusion effects on acute kidney injury (AKI) after transcatheter aortic valve replacement (TAVR). METHODS: A literature search was performed using MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and clinicaltrials.gov from the inception of the databases through December 2015. Studies that reported relative risk, odds ratio or hazard ratio comparing the risks of AKI following TAVR in patients who received periprocedural RBC transfusion were included. Pooled risk ratio (RR) and 95%CI were calculated using a random-effect, generic inverse variance method. RESULTS: Sixteen cohort studies with 4690 patients were included in the analyses to assess the risk of AKI after TAVR in patients who received a periprocedural RBC transfusion. The pooled RR of AKI after TAVR in patients who received a periprocedural RBC transfusion was 1.95 (95%CI: 1.56-2.43) when compared with the patients who did not receive a RBC transfusion. The meta-analysis was then limited to only studies with adjusted analysis for confounders assessing the risk of AKI after TAVR; the pooled RR of AKI in patients who received periprocedural RBC transfusion was 1.85 (95%CI: 1.29-2.67). CONCLUSION: Our meta-analysis demonstrates an association between periprocedural RBC transfusion and a higher risk of AKI after TAVR. Future studies are required to assess the risks of severe AKI after TAVR requiring renal replacement therapy and mortality in the patients who received periprocedural RBC transfusion.
Authors: Arnaud Van Linden; Jörg Kempfert; Ardawan J Rastan; David Holzhey; Johannes Blumenstein; Gerhard Schuler; Friedrich W Mohr; Thomas Walther Journal: Eur J Cardiothorac Surg Date: 2010-12-24 Impact factor: 4.191
Authors: Rutger-Jan Nuis; Josep Rodés-Cabau; Jan-Malte Sinning; Leen van Garsse; Joelle Kefer; Johan Bosmans; Antonio E Dager; Nicolas van Mieghem; Marina Urena; Georg Nickenig; Nikos Werner; Jos Maessen; Parla Astarci; Sergio Perez; Luis M Benitez; Eric Dumont; Ron T van Domburg; Peter P de Jaegere Journal: Circ Cardiovasc Interv Date: 2012-10-09 Impact factor: 6.546
Authors: Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas Journal: Circulation Date: 2014-03-03 Impact factor: 29.690
Authors: Philippe Généreux; Susheel K Kodali; Philip Green; Jean-Michel Paradis; Benoit Daneault; Garvey Rene; Irene Hueter; Isaac Georges; Ajay Kirtane; Rebecca T Hahn; Craig Smith; Martin B Leon; Mathew R Williams Journal: Am J Cardiol Date: 2012-10-04 Impact factor: 2.778
Authors: James M Brown; Sean M O'Brien; Changfu Wu; Jo Ann H Sikora; Bartley P Griffith; James S Gammie Journal: J Thorac Cardiovasc Surg Date: 2009-01 Impact factor: 5.209
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Akeel M Merchant; Javier A Neyra; Abu Minhajuddin; Lauren E Wehrmann; Richard A Mills; Sarah K Gualano; Dharam J Kumbhani; Lynn C Huffman; Michael E Jessen; Amanda A Fox Journal: BMC Anesthesiol Date: 2019-06-11 Impact factor: 2.217
Authors: Pietro Scicchitano; Marco Tucci; Maria Consiglia Bellino; Francesca Cortese; Annagrazia Cecere; Micaela De Palo; Francesco Massari; Pasquale Caldarola; Francesco Silvestris; Marco Matteo Ciccone Journal: Cardiovasc Drugs Ther Date: 2021-06 Impact factor: 3.727